Fabrication of a novel hybrid scaffold for tissue engineered heart valve

Abstract

The aim of this study was to fabricate biomatrix/polymer hybrid scaffolds using an electrospinning technique. Then tissue engineered heart valves were engineered by seeding mesenchymal stromal cells (MSCs) onto the scaffolds. The effects of the hybrid scaffolds on the proliferation of seed cells, formation of extracellular matrix and mechanical properties of tissue engineered heart valves were investigated. MSCs were obtained from rats. Porcine aortic heart valves were decellularized, coated with poly(3-hydroxybutyrate-co-4-hydroxybutyrate) using an electrospinning technique, and reseeded and cultured over a time period of 14 days. In control group, the decellularized valve scaffolds were reseeded and cultured over an equivalent time period. Specimens of each group were examined histologically (hematoxylin-eosin [HE] staining, immunohistostaining, and scanning electron microscopy), biochemically (DNA and 4-hydroxyproline) and mechanically. The results showed that recellularization was comparable to the specimens of hybrid scaffolds and controls. The specimens of hybrid scaffolds and controls revealed comparable amounts of cell mass and 4-hydroxyproline (P>0.05). However, the specimens of hybrid scaffolds showed a significant increase in mechanical strength, compared to the controls (P<0.05). This study demonstrated the superiority of the hybrid scaffolds to increase the mechanical strength of tissue engineered heart valves. And compared to the decellularized valve scaffolds, the hybrid scaffolds showed similar effects on the proliferation of MSCs and formation of extracellular matrix. It was believed that the hybrid scaffolds could be used for the construction of tissue engineered heart valves.

Keywords

tissue engineered heart valve / hybrid scaffold / electrospinning / mesenchymal stem cells

References

[1] SchmidtD., StockU.A., HoerstrupS.P.. Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices. Philos Trans R Soc Lond B Biol Sci, 2007, 362(1484): 1505-1512

[2] SchmidtD., MolA., BreymannC., et al.. Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation, 2006, 114(1Suppl): 125-131

[3] WuH., WanY., CaoX.Y., et al.. Proliferation of chondrocytes on porous poly(DL-lactide)/chitosan scaffolds. Acta Biomaterialia, 2008, 4(1): 76-87

[4] StockU.A., Schenke-LaylandK.. Performance of decellularized xenogeneic tissue in heart valve replacement. Biomaterials, 2006, 27(1): 1-2

[5] KnightR.L., WilcoxH.E., KorossisS.A., et al.. The use of acellular matrices for the tissue engineering of cardiac valves. Proc Inst Mech Eng [H], 2008, 222(1): 129-143

[6] LichtenbergA., CebotariS., TudoracheI., et al.. Biological scaffolds for heart valve tissue engineering. Methods Mol Med, 2007, 140: 309-317

[7] JiangX.G., XuP., HanX., et al.. Biophysics of acellular porcine valved conduits by decellularization with poly ethylene glycol. Acta Med Univ Sci Technol Huazhong (Chinese), 2006, 35(5): 659-661

[8] DongN.G., YeX.F., ShiJ.W., et al.. Comparison on decellularizing methods of biological scaffold with porcine aortic valve for tissue engineering heart valve. Chin J Exp Surg (Chinese), 2005, 22(3): 377

[9] ZhangJ., QiH.X., WangH.J., et al.. Engineering of vascular grafts with genetically modified bone marrow mesenchymal stem cells on poly(propylene carbonate) graft. Artificial Organs, 2006, 30(12): 898-905

[10] KadneraA., HoerstrupaS.P., ZundG., et al.. A new source for cardiovascular tissue engineering: human bone marrow stromal cells. Eur J Cardiothorac Surg, 2002, 21(6): 1055-1060

[11] StockU.A., WiederschainD., KilroyS.M., et al.. Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures. J Cell Biochem, 2001, 81(2): 220-228

[12] Schenke-LaylandK., OpitzF., GrossM., et al.. Complete dynamic repopulation of decellularized heart valves by application of defined physical signals—an in vitro study. Cardiovasc Res, 2003, 60(3): 497-509

[13] KorkusuzF., KorkusuzP., EksiogluF., et al.. In vivo response to biodegradable controlled antibiotic release systems. J Biomed Mater Res, 2001, 55(2): 217-228

[14] FranconiF., MiceliM., AlbertiL., et al.. Effect of gamma-hydroxybutyric acid on human platelet aggregation in vitro. Thromb Res, 2001, 102(3): 255-260

[15] StitzelJ., LiuJ., LeeS.J., et al.. Controlled fabrication of a biological vascular substitute. Biomaterials, 2006, 27(7): 1088-1094

[16] WilliamsonM.R., BlackR., KieltyC.. PCL-PU composite vascular scaffold production for vascular tissue engineering: attachment, proliferation and bioactivity of human vascular endothelial cells. Biomaterials, 2006, 27(19): 3608-3616